Invivotek, a Genesis Drug Discovery and Development (GD3) Company, is a global pre-clinical contract research organization (CRO) specializing in small animal studies for drug discovery and early optimization. Invivotek's facility was opened in 2012 and our first commercial project launched in 2013. Invivotek offers both custom and standard pre-clinical services for drug discovery and development programs for our clients. Invivotek’s portfolio includes animal models and bioassays designed to support in vivo testing of compounds related to Immunology and Inflammation, Oncology, Metabolic, and Cardiovascular diseases. Invivotek’s in vivo testing capabilities are supported by biochemical and molecular biology techniques as well as functional assays with primary cell cultures established from various mouse tissues under disease model and normal conditions. These assays provide tools to study the mechanism of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers. The collective experience across multiple therapeutic areas in conjunction with the business and project management skills of the team working in a state-of-the-art animal facility, position Invivotek as a leading provider of preclinical in vivo services.